Related Experiment Video
Updated: Apr 15, 2026

An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
Design, synthesis, and biological evaluation of novel peptide Gly(3) -MC62 analogues as potential antidiabetic agents
Baowei Yang1,2, Chenyu Zhang1, Xue Li1
1Center of Drug Discovery, State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing, Jiangsu, 210009, China.
Abstract:
Two series of conformationally constrained analogues from Gly(3) -MC62 were designed by scanning the residues Lys(1) , Thr(2) , Met(4) , Lys(5) , Met(7,) and Ala(8) with an i-(i + 2) lactam bridge consisting of a Glutamic acid-xaa-lysine (Glu-Xaa-Lys) scaffold and a diproline fragment. They were synthesized and evaluated for their antihyperglycemic effects. Through screening in normal and mice with diabetes mellitus, peptides II-5, III-3, III-4, and III-5 showed significant improvement in antihyperglycemic and antioxidative activities compared with Gly(3) -MC62, especially the compound III-4. The primary mechanism of the compounds (II-5, III-3, III-4, and III-5) underlying this effect is the islet β-cells against oxidative damage induced by STZ, and III-4-treated mice showed considerable improvement in the preservation of beta cells in the pancreatic islets of DM mice. These data suggested that III-4 could be candidate for the future treatment of diabetes mellitus.
Related Concept Videos
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Insulin: Biosynthesis, Chemistry, and Preparation
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Oral Hypoglycemic Agents: Glinides
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Oral Hypoglycemic Agents: Biguanides and Glitazones
Dipeptidyl Peptidase 4 Inhibitors

